Your Health, We Care
The most common adverse reactions in adults (incidence ≥2%) are nausea, vomiting, abdominal pain, gastrointestinal hemorrhage, anemia, and neutropenia.
The most common adverse reactions in pediatric patients (incidence ≥5%) treated with Fidaxomicin are pyrexia, abdominal pain, vomiting, diarrhea, constipation, increased aminotransferases, and rash.
FDA,2020.05
Fidaxomicin is an antibiotic used to treat Clostridium difficile infections. Its common side effects include gastrointestinal reactions such as abdominal pain, nausea, and vomiting···【more】
Article source：Lucius LaosRelease date：2026-02-28Recommended：24
Fidaxomicinis a macrolide antibiotic developed by Optimer, which is mainly used for the treatment of refractory Clostridium infection, with a novel mechanism of action and signific···【more】
Article source：Lucius LaosRelease date：2024-08-30Recommended：231
Fidaxomicinis a macrolide antibiotic developed by Optimer, which is mainly used for the treatment of refractory Clostridium infection and exerts efficacy by inhibiting bacterial RN···【more】
Article source：Lucius LaosRelease date：2024-08-30Recommended：267
Fidaxomicin is prescribed for the management of Clostridium difficile associated diarrhea in individuals aged 6 months and beyond. It is imperative for patients to remain vigilant ···【more】
Article source：Lucius LaosRelease date：2024-08-05Recommended：232
Fidaxomicin is a pharmaceutical agent specifically indicated for the treatment of diarrhea associated with Clostridium difficile. The assessment of the gravity of adverse events st···【more】
Article source：Lucius LaosRelease date：2024-08-05Recommended：214
Fidaxomicin is a prescription medication that should be administered under the guidance of a physician. Patients are advised to undergo regular examinations, observe any discomfort···【more】
Article source：Lucius LaosRelease date：2024-08-05Recommended：207
Fidaxomicin is a pharmaceutical agent specifically designed to combat infections caused by Clostridium difficile. Prior to initiating treatment with Fidaxomicin, patients are advis···【more】
Article source：Lucius LaosRelease date：2024-07-30Recommended：195
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
